



THE BANBURY CENTER
Cold Spring Harbor Laboratory

MEETING AGENDA

Future Concepts for Disruptive Therapeutics

April 24 to 27, 2022

The Banbury Center, Lloyd Harbor, New York

This meeting was funded by
Ionis Pharmaceuticals

Organizers:

David Ecker, Ionis Pharmaceuticals, and
Michael Hayden, University of British Columbia

In recent decades, new technologies, coupled with a much deeper understanding of the biology of disease processes, have led to breakthroughs in therapy. This meeting convened diverse experts and stakeholders to present new therapeutic concepts and discussed what needs to happen to enable the vision in an innovative and equitable way. Core themes, including new technologies, landscapes, and integration in a world of silos, provided the backbone for these discussions.

SUNDAY, APRIL 24

Afternoon Arrivals and check-in
6:00 pm Reception and dinner

MONDAY, APRIL 25

7:15 am Breakfast

8:30 am **Welcome, Introduction, Meeting Objectives**
Rebecca Leshan, Banbury Center
David Ecker, Ionis Pharmaceuticals



- 9:00 am** **SESSION 1: Emerging Landscapes**
Christopher Lowe, University of Cambridge
Banning Garrett, Singularity University
[virtual] Joe Arron, 23andMe
Michael Hayden, University of British Columbia
Joni Rutter, National Center for Advancing Translational Sciences, NIH
- 12:00 pm** Luncheon
- 1:30 pm** **(continued) SESSION 1: Emerging Landscapes**
Xuanhe Zhao, Massachusetts Institute of Technology
Timothy Broderick, Institute for Human and Machine Cognition
- 2:30 pm** **SESSION 2A: Emerging Platforms I**
Xandra Breakefield, Massachusetts General Hospital & Harvard Medical School
Alfica Sehgal, CAMP4 Therapeutics
Chrystal Louis, CRISPR Therapeutics
Janice Chen, Mammoth Biosciences
- 4:50 pm** **General Discussion & End of Day Wrap-up**
- 6:00 pm** Reception and dinner

TUESDAY, APRIL 26

- 7:15 am** Breakfast
- 8:30 am** **SESSION 2B: Emerging Platforms II**
Frank Bennett, Ionis Pharmaceuticals
Adrian Krainer, Cold Spring Harbor Laboratory
Barry Canton, Ginkgo Bioworks
Kevin Tracey, The Feinstein Institutes for Medical Research
Simone Fishburn, BioCentury Inc.
- 11:30 am** **General Discussion**
- 12:00 pm** Luncheon



- 1:15 pm** **SESSION 3: Trends**
Clarice Aiello, University of California, Los Angeles
Sidney Hecht, Arizona State University
Amy Bernard, Kavli Foundation
Tobias Janowitz, Cold Spring Harbor Laboratory
- 3:45 pm** **SESSION 4: Legal and Ethical Considerations**
Shawneequa Callier, George Washington University
Thomas Wilson Williams, Duke University
- 4:45 pm** **General Discussion & End of Day Wrap-Up**
- 6:00 pm** Reception and dinner

WEDNESDAY, APRIL 27

- 7:15 am** Breakfast
- 8:30 am** **SESSION 5: Global Equity**
Yesim Tozan, New York University
Dan Wattendorf, Bill & Melinda Gates Foundation
- 9:00 am** **Group Discussion**
- 10:15 am** **SESSION 6: Meeting Wrap-Up & Next Steps**
Moderated Group Discussion
- 12:15 pm** Luncheon
- 2:00 pm** Participant departures

— END OF PROGRAM —



PARTICIPANTS LIST

Clarice Aiello, University of California, Los Angeles
Joseph Arron, 23andMe
Frank Bennett, Ionis Pharmaceuticals
Amy Bernard, Kavli Foundation
Xandra Breakefield, Massachusetts General Hospital & Harvard Medical School
Timothy Broderick, Institute for Human and Machine Cognition
Shawneequa Callier, George Washington University
Barry Canton, Ginkgo Bioworks
Janice Chen, Mammoth Biosciences
David Ecker, Ionis Pharmaceuticals
Simone Fishburn, BioCentury Inc.
Banning Garrett, Singularity University
Ryan Hammer, KnowInnovation
Michael Hayden, University of British Columbia
Sidney Hecht, Arizona State University
Tobias Janowitz, Cold Spring Harbor Laboratory
Adrian Krainer, Cold Spring Harbor Laboratory
Chrystal Louis, CRISPR Therapeutics
Christopher Lowe, University of Cambridge
Joni Rutter, National Center for Advancing Translational Sciences, NIH
Alfca Sehgal, CAMP4 Therapeutics
Yesim Tozan, New York University School of Global Public Health
Kevin Tracey, The Feinstein Institutes for Medical Research
Daniel Wattendorf, Bill & Melinda Gates Foundation
Thomas Wilson Williams, Duke Initiative for Science & Society
Xuanhe Zhao, Massachusetts Institute of Technology